A detailed history of China Universal Asset Management Co., Ltd. transactions in Adma Biologics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 44,829 shares of ADMA stock, worth $957,995. This represents 0.1% of its overall portfolio holdings.

Number of Shares
44,829
Previous 27,234 64.61%
Holding current value
$957,995
Previous $304,000 194.74%
% of portfolio
0.1%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$11.21 - $20.03 $197,239 - $352,427
17,595 Added 64.61%
44,829 $896,000
Q2 2024

Jul 19, 2024

SELL
$5.98 - $11.18 $99,483 - $185,990
-16,636 Reduced 37.92%
27,234 $304,000
Q1 2024

Apr 29, 2024

BUY
$4.4 - $6.74 $78,003 - $119,486
17,728 Added 67.81%
43,870 $290,000
Q4 2023

May 21, 2024

SELL
$3.08 - $4.52 $54,602 - $80,130
-17,728 Reduced 40.41%
26,142 $118,000
Q4 2023

Jan 23, 2024

BUY
$3.08 - $4.52 $62,764 - $92,108
20,378 Added 353.54%
26,142 $118,000
Q3 2023

May 21, 2024

BUY
$3.47 - $4.61 $9,892 - $13,143
2,851 Added 97.87%
5,764 $20,000
Q3 2023

Oct 30, 2023

BUY
$3.47 - $4.61 $9,892 - $13,143
2,851 Added 97.87%
5,764 $21,000
Q2 2023

May 21, 2024

SELL
$3.12 - $4.22 $249 - $337
-80 Reduced 2.67%
2,913 $10,000
Q2 2023

Jul 27, 2023

SELL
$3.12 - $4.22 $249 - $337
-80 Reduced 2.67%
2,913 $11,000
Q1 2023

May 21, 2024

BUY
$3.01 - $3.87 $2,991 - $3,846
994 Added 49.72%
2,993 $9,000
Q1 2023

Apr 27, 2023

BUY
$3.01 - $3.87 $2,991 - $3,846
994 Added 49.72%
2,993 $10,000
Q4 2022

May 21, 2024

SELL
$2.47 - $3.88 $103,421 - $162,459
-41,871 Reduced 95.44%
1,999 $7,000
Q4 2022

Jan 31, 2023

BUY
$2.47 - $3.88 $397 - $624
161 Added 8.76%
1,999 $8,000
Q3 2022

Oct 21, 2022

BUY
$2.03 - $2.86 $3,731 - $5,256
1,838 New
1,838 $4,000

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $4.2B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.